Vandetanib has value in non-small-cell lung cancer

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1544, 2006-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vandetanib for the treatment of non-small-cell lung cancer

By Wong Hui-li de Boer Richard H

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 14, 2011-10 ,pp. : 2271-2278

Informa Healthcare

Access to resources Recommend Favorite

Spotlight on Gefitinib in Non-Small-Cell Lung Cancer

By Frampton James E. Easthope Stephanie E.

American Journal of PharmacoGenomics, Vol. 5, Iss. 2, 2005-01 ,pp. : 133-136

Adis International

Access to resources Recommend Favorite

Emerging drugs for non-small-cell lung cancer

By Felip Enriqueta Santarpia Mariacarmela Rosell Rafael

Expert Opinion on Emerging Drugs, Vol. 12, Iss. 3, 2007-09 ,pp. : 449-460

Informa Healthcare

Access to resources Recommend Favorite

Bortezomib with or without docetaxel has modest activity for refractory or recurrent advanced non-small-cell lung cancer

Inpharma, Vol. 1, Iss. 1565, 2006-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

The Vx 001 [TERT572Y] vaccine has shown promise in the treatment of advanced non-small-cell lung cancer

Inpharma, Vol. 1, Iss. 1598, 2007-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite